130 related articles for article (PubMed ID: 29552770)
61. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
62. [Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer].
Zhang R; Li B; Bai P; Li HJ; Li SM; Wu LY; Li W
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):616-20. PubMed ID: 22325224
[TBL] [Abstract][Full Text] [Related]
63. Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines.
Abudabbus A; Badmus JA; Shalaweh S; Bauer R; Hiss D
Curr Pharm Biotechnol; 2017; 18(9):748-757. PubMed ID: 29141543
[TBL] [Abstract][Full Text] [Related]
64. Treatment for advanced cervical cancer: impact on quality of life.
Davidson S
Crit Rev Oncol Hematol; 2011 Jul; 79(1):24-30. PubMed ID: 20810289
[TBL] [Abstract][Full Text] [Related]
65. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
66. In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs.
Simon D; Knebel JW; Baumgartner W; Aufderheide M; Meyer-Lindenberg A; Nolte I
Am J Vet Res; 2001 Nov; 62(11):1825-30. PubMed ID: 11703031
[TBL] [Abstract][Full Text] [Related]
67. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
68. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
69. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
70. The use of ATP bioluminescence assays in selecting a drug screen panel for chemosensitivity testing of uterine cancer cell lines.
Nguyen HN; Sevin BU; Averette HE; Perras J; Donato D; Penalver M
Gynecol Oncol; 1992 May; 45(2):185-91. PubMed ID: 1592285
[TBL] [Abstract][Full Text] [Related]
71. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines.
Hightower RD; Sevin BU; Perras J; Nguyen H; Angioli R; Untch M; Averette H
Cancer Invest; 1993; 11(3):276-82. PubMed ID: 8485650
[TBL] [Abstract][Full Text] [Related]
72. [Basic investigation for classification of anticancer drugs by pharmacological effects].
Takahashi N; Kobayashi M; Itagaki S; Hirano T; Takekuma Y; Sugawara M; Iseki K
Yakugaku Zasshi; 2012; 132(6):777-83. PubMed ID: 22687737
[TBL] [Abstract][Full Text] [Related]
73. In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons.
Schadendorf D; Jurgovsky K; Worm M; Czarnetzki BM
Melanoma Res; 1994 Aug; 4(4):243-9. PubMed ID: 7524835
[TBL] [Abstract][Full Text] [Related]
74. Carboplatin Use in Pregnancy for Stage IB3 Cervical Cancer: Case Report and Review of the Literature.
Rabaiotti E; Girardelli S; Valsecchi L; Bergamini A; Petrone M; Mangili G; Candiani M
J Adolesc Young Adult Oncol; 2020 Jun; 9(3):445-448. PubMed ID: 31794686
[TBL] [Abstract][Full Text] [Related]
75. Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay.
Hightower RD; Sevin BU; Perras JP; Untch M; Angioli R; Ramos R; Averette H
Gynecol Oncol; 1992 Nov; 47(2):186-90. PubMed ID: 1468696
[TBL] [Abstract][Full Text] [Related]
76. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
Wen Y; Gorsic LK; Wheeler HE; Ziliak DM; Huang RS; Dolan ME
Pharmacogenet Genomics; 2011 Aug; 21(8):476-88. PubMed ID: 21642893
[TBL] [Abstract][Full Text] [Related]
77. Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line.
Boike GM; Petru E; Sevin BU; Averette HE; Chou TC; Penalver M; Donato D; Schiano M; Hilsenbeck SG; Perras J
Gynecol Oncol; 1990 Sep; 38(3):315-22. PubMed ID: 2121626
[TBL] [Abstract][Full Text] [Related]
78. Toxicity of anticancer agents mediated by electroporation in vitro.
Jaroszeski MJ; Dang V; Pottinger C; Hickey J; Gilbert R; Heller R
Anticancer Drugs; 2000 Mar; 11(3):201-8. PubMed ID: 10831279
[TBL] [Abstract][Full Text] [Related]
79. The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours.
O'Toole SA; Sheppard BL; McGuinness EP; Gleeson NC; Yoneda M; Bonnar J
Cancer Detect Prev; 2003; 27(1):47-54. PubMed ID: 12600417
[TBL] [Abstract][Full Text] [Related]
80. Tracing of intracellular pH in cancer cells in response to Taxol treatment.
Druzhkova I; Lukina M; Dudenkova V; Ignatova N; Snopova L; Gavrina A; Shimolina L; Belousov V; Zagaynova E; Shirmanova M
Cell Cycle; 2021 Aug; 20(16):1540-1551. PubMed ID: 34308742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
